About Biomanufacturing Services

Cedars-Sinai Biomanufacturing Center

(Coming in 2020)

Cedars-Sinai is developing a state-of-the art new biomanufacturing facility called the Cedars-Sinai Biomanufacturing Center (CBC). The CBC will comprise of a cGMP cell manufacturing facility housing multiple cleanroom cell production suites and process development rooms for producing the next generation of cell and gene therapies. These new therapies will be used for human IND-enabling clinical trials. We will serve Cedars-Sinai faculty, external academic, clinical and commercial investigators. We hope to spur economic growth in regenerative medicine with innovative manufacturing of clinical-grade regenerative therapies suitable for investigational use in humans. With world class expertise in stem cell (iPSC) biology, bioprocessing, translational, regulatory and manufacturing, this new facility will provide a much-needed biomanufacturing center in Southern California.

Quality Policy

The CBC is committed to manufacturing the highest quality innovative cell and gene therapy products that meet or exceed our customer’s requirements and expectations. We apply good scientific practices to provide diverse quality products and services. As dedicated partners in biomanufacturing, we pledge to provide the highest levels of quality and safety of the manufactured products through robust and effective quality systems, process controls, rigorous performance criteria and testing.

We will strive to maintain compliance with CGMP regulations, with a focus on continuous improvement, monitoring and measurement of our core process metrics to ensure effectiveness.

About the iPSC Core

Browse Our Cell Line Catalog

Browse Cell Line Catalog

Hundreds of already established lines spanning over 30 degenerative diseases.